logo

Ideaya Biosciences (IDYA)



Trade IDYA now with
  Date
  Headline
9/6/2022 6:05:33 AM IDEAYA Dose\es First-Patient-In For Phase I Trial Of Darovasertib Monotherapy In (Neo)Adjuvant Uveal Melanoma
8/29/2022 6:04:54 AM IDEAYA Biosciences Achieves Preclinical Development Milestone In Ongoing Collaboration With GSK
8/15/2022 6:02:31 AM IDEAYA Biosciences Q2 Loss Per Share $0.57 Vs Loss $0.36 Last Year
7/27/2022 6:06:33 AM IDEAYA Announces IDE397 Program Update And CtDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation
7/27/2022 6:02:00 AM IDEAYA Collaborates With Amgen To Evaluate MAT2A-PRMT5 Synthetic Lethality Combination In MTAP Deleted Tumors
6/28/2022 6:04:56 AM IDEAYA Announces Selection Of Potential First-in-class Pol Theta Helicase Development Candidate
5/10/2022 6:13:10 AM IDEAYA Biosciences Q1 Net Loss $14.0 Mln Vs Net Losss $18.2 Mln Last Year
5/2/2022 6:02:29 AM IDEAYA Biosciences Receives Orphan Drug Designation For Darovasertib For Uveal Melanoma
3/16/2022 4:47:32 PM Wedbush Is Increasing IDEAYA Biosciences (IDYA) FY22 Estimate To -1.66 From -1.69
3/16/2022 4:47:16 PM Wedbush Is Raising IDEAYA Biosciences (IDYA) Q4 22 Estimate To -0.47 From -0.48
3/16/2022 4:47:03 PM Wedbush Is Raising IDEAYA Biosciences (IDYA) Q3 22 Estimate To -0.43 From -0.44
3/16/2022 4:46:41 PM Wedbush Is Raising IDEAYA Biosciences (IDYA) Q1 22 Estimate To -0.36 From -0.37
3/16/2022 4:46:09 PM Wedbush Reiterates IDEAYA Biosciences (IDYA) At Outperform With $34 Price Target
3/15/2022 6:11:26 AM IDEAYA Biosciences Q4 Net Loss $18.2 Mln Vs Loss $5.1 Mln Last Year